NCT04932148 INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)
| NCT ID | NCT04932148 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Queensland |
| Condition | Kidney Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 372 participants |
| Start Date | 2022-07-06 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 372 participants in total. It began in 2022-07-06 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The INCH-HD trial will test if incremental HD preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥ 18 years of age) and 2. Commencing HD as their initial dialysis therapy and 3. Able to give informed consent Exclusion Criteria: 1. Urine output \<0.5Litres/day 2. Unlikely to be on HD for ≥1 year.
Contact & Investigator
Peter Kerr, Prof
PRINCIPAL INVESTIGATOR
University of Queensland, Monash University
Frequently Asked Questions
Who can join the NCT04932148 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04932148 currently recruiting?
Yes, NCT04932148 is actively recruiting participants. Contact the research team at inch-hd.trial@uq.edu.au for enrollment information.
Where is the NCT04932148 trial being conducted?
This trial is being conducted at Concord, Australia, Frenchs Forest, Australia, Kogarah, Australia, Liverpool, Australia and 11 additional locations.
Who is sponsoring the NCT04932148 clinical trial?
NCT04932148 is sponsored by The University of Queensland. The principal investigator is Peter Kerr, Prof at University of Queensland, Monash University. The trial plans to enroll 372 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.